BACKGROUND: Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU). It is unclear whether this occurs because such tumours have better prognosis or they are more sensitive to 5-FU treatment. PATIENTS AND METHODS: Associations between TS, DPD and TP levels, determined by tissue microarrays and immunohistochemistry, and survival was evaluated in 945 CRC patients according to treatment status. RESULTS: Low TS and DPD expression associated with worse prognosis in stage II [hazard ratio (HR) = 1.69, 95% confidence interval (CI) (1.09-2.63) and HR = 1.92 (95% CI 1.23-2.94), respectively] and stage III CRC patients treated by surgery alone [HR = 1.39 (95% CI 0.92-2.13) and HR = 1.49 (95% CI 1.02-2.17), respectively]. Low TS, DPD and TP associated with trends for better outcome in stage III patients treated with 5-FU [HR = 0.81 (95% CI 0.49-1.33), HR = 0.70 (95% CI 0.42-1.15) and HR = 0.66 (95% CI 0.39-1.12), respectively]. CONCLUSION: Low TS and DPD expression are prognostic for worse outcome in CRC patients treated by surgery alone, whereas low TS, DPD and TP expression are prognostic for better outcome in patients treated with 5-FU chemotherapy. These results provide indirect evidence that low TS, DPD and TP protein expression are predictive of good response to 5-FU chemotherapy.
BACKGROUND:Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU). It is unclear whether this occurs because such tumours have better prognosis or they are more sensitive to 5-FU treatment. PATIENTS AND METHODS: Associations between TS, DPD and TP levels, determined by tissue microarrays and immunohistochemistry, and survival was evaluated in 945 CRCpatients according to treatment status. RESULTS: Low TS and DPD expression associated with worse prognosis in stage II [hazard ratio (HR) = 1.69, 95% confidence interval (CI) (1.09-2.63) and HR = 1.92 (95% CI 1.23-2.94), respectively] and stage III CRCpatients treated by surgery alone [HR = 1.39 (95% CI 0.92-2.13) and HR = 1.49 (95% CI 1.02-2.17), respectively]. Low TS, DPD and TP associated with trends for better outcome in stage III patients treated with 5-FU [HR = 0.81 (95% CI 0.49-1.33), HR = 0.70 (95% CI 0.42-1.15) and HR = 0.66 (95% CI 0.39-1.12), respectively]. CONCLUSION: Low TS and DPD expression are prognostic for worse outcome in CRCpatients treated by surgery alone, whereas low TS, DPD and TP expression are prognostic for better outcome in patients treated with 5-FU chemotherapy. These results provide indirect evidence that low TS, DPD and TP protein expression are predictive of good response to 5-FU chemotherapy.
Authors: D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2006-10-23 Impact factor: 44.544
Authors: J L Westra; H Hollema; M Schaapveld; I Platteel; K A Oien; W N Keith; R Mauritz; G J Peters; C H C M Buys; R M W Hofstra; J Th M Plukker Journal: Ann Oncol Date: 2005-07-12 Impact factor: 32.976
Authors: T Takenoue; H Nagawa; K Matsuda; S Fujii; M E Nita; K Hatano; J Kitayama; T Tsuruo; T Muto Journal: Ann Surg Oncol Date: 2000-04 Impact factor: 5.344
Authors: B van Triest; H M Pinedo; Y van Hensbergen; K Smid; F Telleman; P S Schoenmakers; C L van der Wilt; J A van Laar; P Noordhuis; G Jansen; G J Peters Journal: Clin Cancer Res Date: 1999-03 Impact factor: 12.531
Authors: Joana Savva-Bordalo; João Ramalho-Carvalho; Manuela Pinheiro; Vera L Costa; Angelo Rodrigues; Paula C Dias; Isabel Veiga; Manuela Machado; Manuel R Teixeira; Rui Henrique; Carmen Jerónimo Journal: BMC Cancer Date: 2010-09-01 Impact factor: 4.430